PE20170908A1 - VARIANTES DE INTERFERON a2b - Google Patents
VARIANTES DE INTERFERON a2bInfo
- Publication number
- PE20170908A1 PE20170908A1 PE2017000753A PE2017000753A PE20170908A1 PE 20170908 A1 PE20170908 A1 PE 20170908A1 PE 2017000753 A PE2017000753 A PE 2017000753A PE 2017000753 A PE2017000753 A PE 2017000753A PE 20170908 A1 PE20170908 A1 PE 20170908A1
- Authority
- PE
- Peru
- Prior art keywords
- aglycosilated
- alfa2b
- ifn
- joins
- domain
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title abstract 2
- 108010050904 Interferons Proteins 0.000 title abstract 2
- 229940079322 interferon Drugs 0.000 title abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 abstract 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014904326A AU2014904326A0 (en) | 2014-10-29 | Interferon alpha 2b variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170908A1 true PE20170908A1 (es) | 2017-07-12 |
Family
ID=55851917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000753A PE20170908A1 (es) | 2014-10-29 | 2015-10-23 | VARIANTES DE INTERFERON a2b |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10544199B2 (enExample) |
| EP (1) | EP3212216A4 (enExample) |
| JP (2) | JP6730271B2 (enExample) |
| KR (1) | KR102639037B1 (enExample) |
| CN (1) | CN107106656B (enExample) |
| AU (1) | AU2015337858B2 (enExample) |
| CA (1) | CA2965414C (enExample) |
| CL (1) | CL2017001070A1 (enExample) |
| CO (1) | CO2017004318A2 (enExample) |
| EA (1) | EA037749B1 (enExample) |
| IL (1) | IL251822B2 (enExample) |
| MX (1) | MX393988B (enExample) |
| PE (1) | PE20170908A1 (enExample) |
| PH (1) | PH12017500785A1 (enExample) |
| SG (1) | SG11201703251TA (enExample) |
| UA (1) | UA125637C2 (enExample) |
| WO (1) | WO2016065409A1 (enExample) |
| ZA (1) | ZA201702891B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA034989B1 (ru) | 2011-10-28 | 2020-04-15 | Тева Фармасьютикал Австралия Пти Лтд | Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон |
| DK3677591T5 (da) | 2013-04-29 | 2024-08-26 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| ES2657060T3 (es) * | 2013-07-18 | 2018-03-01 | Vib Vzw | Fusoquinas que implican citoquinas con afinidades de unión por el receptor fuertemente reducidas |
| UA119352C2 (uk) * | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| EA037749B1 (ru) * | 2014-10-29 | 2021-05-18 | Тева Фармасьютикалз Острэйлиа Пти Лтд | ВАРИАНТЫ ИНТЕРФЕРОНА 2b |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| WO2017123548A1 (en) * | 2016-01-14 | 2017-07-20 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment |
| EP3411407B1 (en) * | 2016-02-05 | 2024-04-03 | Orionis Biosciences BV | Bispecific signaling agents and uses thereof |
| WO2018014068A1 (en) * | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd | Attenuated type i ifn cd47 combination therapy |
| EP3487522A4 (en) * | 2016-07-19 | 2020-04-01 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd47 combination therapy |
| EP3576765B1 (en) | 2017-02-06 | 2025-07-16 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| US20200354424A1 (en) * | 2018-01-26 | 2020-11-12 | Orionis Biosciences, Inc. | Xcr1 binding agents and uses thereof |
| US20210024631A1 (en) * | 2018-03-28 | 2021-01-28 | Orionis Biosciences, Inc. | Bi-functional proteins and construction thereof |
| US12162947B2 (en) | 2018-09-04 | 2024-12-10 | Nanjing Umab-Biopharma Co., Ltd. | Fusion protein and its applicaton in preparing medicine for treating tumor and/or viral infection |
| WO2020048454A1 (zh) * | 2018-09-04 | 2020-03-12 | 南京优迈生物科技有限公司 | 融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用 |
| IL293450A (en) | 2019-12-03 | 2022-07-01 | Evotec Int Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| AR117715A1 (es) | 2019-12-17 | 2021-08-25 | Univ Nacional Del Litoral Unl | Interferón hiperglicosilado con inmunogenicidad reducida |
| US11767353B2 (en) * | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
| WO2023016568A1 (zh) * | 2021-08-12 | 2023-02-16 | 上海才致药成生物科技有限公司 | 一种双特异性重组蛋白及其用途 |
| CN119584982A (zh) * | 2022-05-18 | 2025-03-07 | 武田药品工业株式会社 | 抗cd38融合蛋白制剂 |
| CA3257502A1 (en) | 2022-05-27 | 2023-11-30 | Takeda Pharmaceutical Company Limited | CD38 BINDING FUSION PROTEIN ASSAY |
| WO2024069240A2 (en) | 2022-09-29 | 2024-04-04 | Takeda Pharmaceutical Company Limited | Cd38-binding fusion protein combination therapy |
| CN121127493A (zh) | 2023-05-08 | 2025-12-12 | 豪夫迈·罗氏有限公司 | 靶向干扰素 α 融合蛋白及使用方法 |
Family Cites Families (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2148299B (en) | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
| US4908431A (en) | 1986-01-22 | 1990-03-13 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human kininogen and methods of preparing same |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5976531A (en) | 1990-04-19 | 1999-11-02 | The Dow Chemical Company | Composite antibodies of human subgroup IV light chain capable of binding to tag-72 |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| CZ283717B6 (cs) | 1991-03-06 | 1998-06-17 | MERCK Patent Gesellschaft mit beschränkter Haftung | Chimérická monoklonální protilátka, expresní vektory a farmaceutický prostředek |
| JP3370324B2 (ja) | 1991-04-25 | 2003-01-27 | 中外製薬株式会社 | ヒトインターロイキン−６受容体に対する再構成ヒト抗体 |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US6042828A (en) | 1992-09-07 | 2000-03-28 | Kyowa Hakko Kogyo Co., Ltd. | Humanized antibodies to ganglioside GM2 |
| EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
| US5441734A (en) | 1993-02-25 | 1995-08-15 | Schering Corporation | Metal-interferon-alpha crystals |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| CA2163012C (en) | 1994-03-17 | 2009-12-08 | Catherine A. Kettleborough | Anti-egfr single-chain fvs and anti-egfr antibodies |
| ES2167391T3 (es) | 1994-09-16 | 2002-05-16 | Merck Patent Gmbh | Inmunoconjugados ii. |
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| EP2258726A1 (en) | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
| DE69621940T2 (de) | 1995-08-18 | 2003-01-16 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| IL126772A0 (en) | 1996-05-04 | 1999-08-17 | Zeneca Ltd | Monoclonal antibody of cea conjugates comprising said antibody and their therapeutic use in an adept system |
| US6417337B1 (en) | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| GB9709421D0 (en) | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
| EP1881005B1 (en) * | 1997-07-14 | 2013-04-03 | Bolder Biotechnology, Inc. | Derivatives of G-CSF and related proteins |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| AU766190B2 (en) | 1998-10-16 | 2003-10-09 | Biogen Idec Ma Inc. | Interferon-beta fusion proteins and uses |
| JP2002543760A (ja) | 1998-12-09 | 2002-12-24 | 達治 関 | ヒト型糖鎖をもつ糖タンパク質の生産方法 |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| KR100731826B1 (ko) * | 1999-01-14 | 2007-06-22 | 볼더 바이오테크놀로지 인코퍼레이티드 | 유리 시스테인 잔기를 함유하는 단백질의 제조 방법 |
| NZ539776A (en) | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
| JP4778617B2 (ja) | 1999-03-12 | 2011-09-21 | ジョージタウン ユニバーシティ | マトリプターゼ、セリンプロテアーゼおよびその応用 |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| CN1406249B (zh) | 2000-02-11 | 2010-06-16 | 默克专利股份有限公司 | 增加基于抗体的融合蛋白的循环半衰期 |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| US7521047B2 (en) | 2000-05-12 | 2009-04-21 | Gpc Biotech Ag | Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells |
| AU6541801A (en) | 2000-06-22 | 2002-01-02 | Idec Pharma Corp | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| CA2412701A1 (en) | 2000-06-28 | 2002-01-03 | Glycofi, Inc. | Methods for producing modified glycoproteins |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| CA2431600C (en) | 2000-12-12 | 2012-04-17 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| EP1399483B1 (en) | 2001-01-05 | 2010-04-14 | Pfizer Inc. | Antibodies to insulin-like growth factor i receptor |
| FR2823764B1 (fr) | 2001-04-24 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides du gene ifn alpha-17 |
| US20020193569A1 (en) | 2001-06-04 | 2002-12-19 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| CA2451680C (en) | 2001-07-03 | 2011-04-19 | Genentech, Inc. | Human dr4 antibodies and uses thereof |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| AR035119A1 (es) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| KR100668538B1 (ko) | 2002-01-09 | 2007-01-16 | 메다렉스, 인코포레이티드 | Ｃｄ３０에 대한 인간 모노클로날 항체 |
| WO2003074567A2 (en) | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Internalizing anti-cd74 antibodies and methods of use |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7202346B2 (en) | 2002-07-03 | 2007-04-10 | Immunogen Inc. | Antibodies to non-shed Muc1 and Muc16, and uses thereof |
| EP1539950A1 (en) | 2002-09-09 | 2005-06-15 | Nautilus Biotech | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
| AU2003263552A1 (en) | 2002-09-09 | 2004-03-29 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| MXPA05008704A (es) | 2003-02-18 | 2005-10-05 | Merck Patent Gmbh | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| PL1684869T3 (pl) | 2003-11-04 | 2011-12-30 | Novartis Vaccines & Diagnostics Inc | Sposoby leczenia nowotworów wywodzących się z limfocytów B |
| EP1765853B1 (en) * | 2004-01-08 | 2015-10-28 | ratiopharm GmbH | O-linked glycosylation of G-CSF peptides |
| BRPI0507489A (pt) | 2004-02-06 | 2007-07-10 | Morphosys Ag | anticorpos humanos de anti-cd38 e para os seus usos |
| SI2511297T1 (sl) | 2004-02-06 | 2015-07-31 | Morphosys Ag | Proti -CD38 humana protitelesa in njihova uporaba |
| US8034352B2 (en) | 2005-04-06 | 2011-10-11 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
| WO2005086875A2 (en) | 2004-03-11 | 2005-09-22 | City Of Hope | A humanized anti-cea t84.66 antibody and uses thereof |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| AU2005259221B2 (en) | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
| WO2006044643A2 (en) | 2004-10-15 | 2006-04-27 | Seattle Genetics, Inc. | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| IL316252A (en) | 2005-03-23 | 2024-12-01 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
| AR053489A1 (es) | 2005-05-24 | 2007-05-09 | Morphosys Ag | Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano |
| MX2007014889A (es) | 2005-05-26 | 2008-02-19 | Schering Corp | Fusion de interferon-inmunoglobulina g. |
| CN101304758B (zh) | 2005-06-29 | 2013-08-21 | 维兹曼科学研究所耶达研究与发展有限公司 | 重组干扰素α2（IFNα2）突变体 |
| HRP20160875T1 (hr) | 2005-07-18 | 2016-09-23 | Amgen Inc. | Humana anti-b7rp1 neutralizirajuća antitijela |
| EA016186B1 (ru) | 2005-09-26 | 2012-03-30 | Медарекс, Инк. | Человеческие моноклональные антитела к cd70 и их применение |
| US20070190068A1 (en) | 2005-10-10 | 2007-08-16 | Richard Hart | uPAR-binding molecule-drug conjugates and uses thereof |
| SG10201400973XA (en) | 2005-10-12 | 2014-08-28 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| EP1954720A1 (en) | 2005-10-31 | 2008-08-13 | The Government of the United States of America, as represented by the Secretary of Health and Human Services, National Institutes of Health | Antibodies and immunotoxins that target human glycoprotein nmb |
| GB0525214D0 (en) | 2005-12-12 | 2006-01-18 | Bioinvent Int Ab | Biological materials and uses thereof |
| CN101045156B (zh) | 2006-03-29 | 2012-05-02 | 刘宏利 | 特异靶向性药物及其用途 |
| EP1878747A1 (en) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
| FR2905375A1 (fr) | 2006-08-29 | 2008-03-07 | Biomethodes Sa | Variants ameliores de l'interferon alpha humain |
| CA2660795C (en) | 2006-09-18 | 2014-11-18 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
| EP3753576A1 (en) | 2006-09-26 | 2020-12-23 | Genmab A/S | Combination treatment of cd38-expressing tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| CN101687037B (zh) | 2007-05-08 | 2013-07-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗muc16抗体和抗体药物偶联物 |
| WO2008145139A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Fusion or linked proteins with extended half life |
| US8248984B2 (en) | 2007-06-20 | 2012-08-21 | I Squared Llc | System and method for interfacing devices |
| CA2695382A1 (en) | 2007-08-01 | 2009-02-05 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health Of Human Services, National Institutes Of | A fold-back diabody diphtheria toxin immunotoxin and methods of use |
| EP2190879A1 (en) * | 2007-08-01 | 2010-06-02 | Glaxo Group Limited | Novel antibodies |
| US20090076249A1 (en) | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
| EP2853267B1 (en) | 2007-09-21 | 2016-12-07 | The Regents of the University of California | Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| CA2708291A1 (en) * | 2007-12-10 | 2009-06-18 | National Research Council Of Canada | Production of recombinant interferon proteins |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| DK2238168T3 (da) | 2007-12-26 | 2014-08-25 | Biotest Ag | Midler, der er målrettet mod cd138 og anvendelser deraf |
| US8187601B2 (en) | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
| BRPI1009460A2 (pt) | 2009-03-16 | 2016-03-01 | Cephalon Australia Pty Ltd | domínio de ligação do anticorpo, anticorpo, uso de um domínio de ligação ou anticorpo, método para detectar a presença de células cancerígenas em uma amostra. |
| PT2580243T (pt) | 2010-06-09 | 2020-01-22 | Genmab As | Anticorpos contra cd38 humana |
| US8909257B2 (en) | 2010-06-19 | 2014-12-09 | Qualcomm Incorporated | Positioning protocol conveyance |
| LT2621531T (lt) | 2010-09-27 | 2017-04-10 | Morphosys Ag | Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui |
| US9505826B2 (en) | 2010-12-22 | 2016-11-29 | Teva Pharmaceuticals Australia Pty Ltd | Modified antibody with improved half-life |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| AU2012315474B2 (en) * | 2011-09-30 | 2017-10-26 | Teva Pharmaceuticals Australia Pty Ltd. | Antibodies against TL1a and uses thereof |
| EA034989B1 (ru) | 2011-10-28 | 2020-04-15 | Тева Фармасьютикал Австралия Пти Лтд | Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон |
| WO2013107791A1 (en) | 2012-01-20 | 2013-07-25 | Vib Vzw | Targeted mutant alpha-helical bundle cytokines |
| WO2013134138A1 (en) | 2012-03-03 | 2013-09-12 | Immungene, Inc. | Engineered antibody-interferon mutant fusion molecules |
| WO2014028502A1 (en) * | 2012-08-13 | 2014-02-20 | ImmunGene Inc. | Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases |
| EP2948427A2 (de) | 2013-01-25 | 2015-12-02 | Covestro Deutschland AG | Sicherheitselement mit volumenhologramm und druckmerkmal |
| DK3677591T5 (da) | 2013-04-29 | 2024-08-26 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| EA037749B1 (ru) * | 2014-10-29 | 2021-05-18 | Тева Фармасьютикалз Острэйлиа Пти Лтд | ВАРИАНТЫ ИНТЕРФЕРОНА 2b |
| EP3487522A4 (en) * | 2016-07-19 | 2020-04-01 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd47 combination therapy |
-
2015
- 2015-10-23 EA EA201790934A patent/EA037749B1/ru unknown
- 2015-10-23 KR KR1020177014309A patent/KR102639037B1/ko active Active
- 2015-10-23 CA CA2965414A patent/CA2965414C/en active Active
- 2015-10-23 US US14/921,420 patent/US10544199B2/en active Active
- 2015-10-23 MX MX2017005481A patent/MX393988B/es unknown
- 2015-10-23 UA UAA201705168A patent/UA125637C2/uk unknown
- 2015-10-23 IL IL251822A patent/IL251822B2/en unknown
- 2015-10-23 WO PCT/AU2015/050654 patent/WO2016065409A1/en not_active Ceased
- 2015-10-23 PE PE2017000753A patent/PE20170908A1/es unknown
- 2015-10-23 SG SG11201703251TA patent/SG11201703251TA/en unknown
- 2015-10-23 AU AU2015337858A patent/AU2015337858B2/en active Active
- 2015-10-23 JP JP2017523394A patent/JP6730271B2/ja active Active
- 2015-10-23 EP EP15854166.4A patent/EP3212216A4/en active Pending
- 2015-10-23 CN CN201580064412.4A patent/CN107106656B/zh active Active
-
2017
- 2017-04-25 ZA ZA2017/02891A patent/ZA201702891B/en unknown
- 2017-04-26 PH PH12017500785A patent/PH12017500785A1/en unknown
- 2017-04-28 CL CL2017001070A patent/CL2017001070A1/es unknown
- 2017-04-28 CO CONC2017/0004318A patent/CO2017004318A2/es unknown
-
2019
- 2019-12-11 US US16/710,574 patent/US11319356B2/en active Active
-
2020
- 2020-03-17 JP JP2020046259A patent/JP6957666B2/ja active Active
-
2022
- 2022-03-31 US US17/709,510 patent/US20220220184A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170908A1 (es) | VARIANTES DE INTERFERON a2b | |
| PE20170471A1 (es) | Polipeptidos receptores formulados y metodos relacionados | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| PE20170286A1 (es) | Diacuerpos heterodimericos biespecificos y sus usos | |
| MX2025007532A (es) | Receptores de antigenos quimericos para el tratamiento del cancer | |
| BR112017003582A2 (pt) | anticorpos, composições e usos | |
| MX2023008559A (es) | Proteínas de fusión fc heterodiméricas il15/il15ra. | |
| CO2017005650A2 (es) | Anticuerpos anti-interleucina-33 | |
| CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
| MX2016014926A (es) | Dominios variables de inmunoglobulina mejorados. | |
| MX421100B (es) | Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso | |
| CO2017000507A2 (es) | Receptor quimérico de antígeno bcma | |
| EA202090931A3 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
| AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
| MX2016011619A (es) | Anticuerpos anti-egfrviii y usos de los mismos. | |
| PE20161392A1 (es) | Combinacion de lenalidomida y constructo de polipeptido, y sus usos | |
| PE20170953A1 (es) | ANTICUERPOS ANTI-CD79b Y METODOS DE USO | |
| BR112017013981A2 (pt) | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer | |
| MX2016010128A (es) | Acoplador trifuncional de antigeno de celulas t y metodos y usos del mismo. | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| AR103726A1 (es) | Cristales de anticuerpos monoclonales anti-pd-1 humanos | |
| MX2015010146A (es) | Sitios especificos para modificar anticuerpos para hacer inmunoconjugados. | |
| NZ749279A (en) | Compositions and methods related to engineered fc constructs | |
| PH12016501937A1 (en) | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage | |
| MX2018004121A (es) | Receptores de antigeno y usos de los mismos. |